In 2023, The Prescription Drugs Market size amounted to USD 0.97 Billion & is estimated to reach USD 1.89 Billion by 2031 and increase at a compound annual growth rate of 8.6% between 2024 and 2031.
The Prescription Drugs Market refers to the global pharmaceutical industry's segment that focuses on the development, manufacturing, marketing, and distribution of prescription medications. Prescription drugs, also known as prescription or prescription-only medicines, can only be obtained with a valid prescription from a licensed healthcare provider, such as a doctor or a nurse practitioner. The prescription drug market encompasses a wide range of therapeutic areas and medications designed to treat various medical conditions. These medications undergo rigorous research, clinical trials, and regulatory approval processes to ensure their safety and efficacy before they are made available to patients. Research and Development (R&D) is pharmaceutical companies invest heavily in research to discover and develop new drugs. This involves identifying potential drug candidates, conducting preclinical studies, and running clinical trials to test the safety and effectiveness of the medications. Regulatory Approval is Before a prescription drug can be marketed and sold; it must receive approval from regulatory agencies such as the U.S.
Get More Information on Prescription Drugs Market - Request Sample Report
These agencies evaluate the scientific data from clinical trials to ensure the drug's benefits outweigh its risks. Manufacturing is Once a prescription drug receives regulatory approval, pharmaceutical companies engage in large-scale manufacturing to produce the medication in quantities that can meet demand while maintaining quality and consistency. Marketing and Distribution Prescription drugs are marketed to healthcare professionals who can prescribe them, such as doctors, specialists, and other licensed practitioners. Pharmaceutical companies engage in marketing efforts to educate healthcare providers about the drug's benefits, usage, and potential side effects. Distribution involves getting the medications to pharmacies, hospitals, and other healthcare facilities. Sales and Profitability The prescription drugs market is a significant contributor to the revenue and profitability of pharmaceutical companies. Patents and exclusivity periods granted for new drugs allow companies to have a period of market exclusivity during which they can recoup their research and development costs and generate profits. Generic Competition is Once the patents on a brand-name prescription drug expire, other pharmaceutical companies can produce and market generic versions of the medication. Generic drugs are usually more affordable alternatives to their brand-name counterparts and can significantly impact the market dynamics. Healthcare and Patient Access Prescription drugs play a crucial role in managing and treating various medical conditions, improving patient outcomes, and enhancing the overall quality of healthcare. However, issues related to drug pricing, accessibility, and affordability can be significant concerns, leading to discussions about healthcare policy, insurance coverage, and drug pricing regulations. The Prescription Drugs Market is a complex and dynamic sector that intertwines scientific advancements, regulatory oversight, healthcare provider involvement, and patient needs. It is influenced by evolving medical research, economic factors, changing demographics, and advancements in technology.
DRIVERS:
Advances in medical research and technology lead to the discovery of new drug candidates and treatment approaches.
Consumer and Physician Awareness is the driver of the Prescription Drugs Market.
Awareness and education about available treatment options influence prescription patterns. Effective marketing campaigns and physician education efforts by pharmaceutical companies can impact the adoption of new medications.
RESTRAIN:
The pricing of certain prescription drugs, especially for innovative and specialty medications, can be prohibitively high.
The prescription drugs market is being held back by intellectual property challenges.
Patent protections granted to pharmaceutical companies can create barriers to generic competition. While patents incentivize innovation, they can also lead to extended periods of market exclusivity, delaying the availability of more affordable generic alternatives.
OPPORTUNITY:
Pharmaceutical companies are increasingly focusing on rare diseases that have limited treatment options.
Biotechnology and Biosimilars is the opportunity for the Prescription Drugs Market.
The development of biosimilars, which are similar to biologic drugs, presents opportunities for cost savings and increased patient access to biologic therapies.
CHALLENGES:
Developing a new prescription drug involves substantial financial investments in research and clinical trials.
Drug Pricing and Affordability are the challenges of the Prescription Drugs Market.
Pricing prescription drugs, especially for specialty medications and innovative therapies, can lead to affordability issues for patients and healthcare systems.
Russia's situation differs from that of Ukraine. Although direct restrictions on pharmaceuticals are unlikely to be imposed in the near future, be extremely harmful to Russia's access to healthcare and medications. Suppliers to the Russian Pharmaceutical Manufacturers Association have already begun to hinder the flow of pharmaceutical raw materials to Russian facilities, making further supply contracts very hard to obtain. The Russia-Ukraine conflict could last until 2024. The consequences of this conflict will continue to stymie efforts to increase access to medications in Ukraine, particularly given the country's weak currency, which makes imports more expensive. Due to this war between Ukraine and Russia, there has been a big decline in the prescription drugs market all over Europe, due to this war, the supply of raw materials is taking a long time, as a result of which this market has decreased by 2.4-4.3%. is expected to cause damage.
IMPACT OF ONGOING RECESSION
According to the findings of a recent poll conducted by the independent Centre for Studying Health System Change in Washington, DC, the economic downturn had no impact on the capacity of US residents to get prescription medications. In the United States, health insurance is primarily supplied via employment. As the number of uninsured individuals increased by more than 22%, from 76.2 million in 2019 to 93.5 million in 2021, it was assumed that the proportion of people having problems paying for prescription medications would increase. In an ongoing recession, the prescription drugs market is more profitable by up to 3.2-4.5% in this period.
By Product Type
Prescription Drugs
Orphan
Generics
By Therapy
Immunosuppressants
Oncology
Sensory Organs
Vaccines
Anticoagulants
Anti-diabetics
Others
By Distribution Channel
Retail Pharmacies & Drug Stores
Hospital Pharmacies
Online Pharmacies
North America
US
Canada
Mexico
Europe
Eastern Europe
Poland
Romania
Hungary
Turkey
Rest of Eastern Europe
Western Europe
Germany
France
UK
Italy
Spain
Netherlands
Switzerland
Austria
Rest of Western Europe
Asia Pacific
China
India
Japan
South Korea
Vietnam
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
Middle East
UAE
Egypt
Saudi Arabia
Qatar
Rest of Middle East
Africa
Nigeria
South Africa
Rest of Africa
Latin America
Brazil
Argentina
Colombia
Rest of Latin America
REGIONAL ANALYSIS
North America: In North America, the market size was Some of the major factors for North America's dominance in the worldwide market include the region's rising need for efficient and innovative goods, particularly due to the high incidence of many chronic conditions. These characteristics, together with high healthcare expenditure, strong and vigorous R&D for medications in the region, and the existence of important corporations in the region involved in the production of generic counterparts of key drugs, account for the region's leading share of the worldwide market.
Asia Pacific: During the projection period, Asia-Pacific is expected to have a slightly higher CAGR. The market is expected to be driven by new product releases in the area and rising demand for prescription pharmaceuticals. The presence of a large prospective patient population, as well as greater awareness of chronic and severe ailments among individuals, are expected to fuel market expansion in Asia Pacific over the forecast period.
Some major key players in Prescription Drugs Market are Novartis AG, F. Hoffmann-La Roche Ltd, Pfizer, Inc., Johnson & Johnson Services, Inc. Sanofi, AbbVie, Inc., AstraZeneca, Merck & Co., Inc., GlaxoSmithKline pic., CELGENE CORPORATION and other players.
In 2021: Lupin Pharmaceuticals, Inc. announced the introduction of Mycophenolic acid delayed-release tablets in the United States for the prevention of organ rejection in kidney transplant patients.
In 2021: Dr Reddy's Laboratories Ltd. announced the availability of the generic counterpart of Geodon (Ziprasidone Mesylate) injectable, a medication used in the treatment of schizophrenia in the United States.
In 2020: In the United States, Dr Reddy's Laboratories Ltd. announced the availability of the generic form of Vimovo (naproxen and esomeprazole magnesium), a medicine used to treat inflammation.
| Report Attributes | Details |
| Market Size in 2023 | US$ 0.97 Bn |
| Market Size by 2031 | US$ 1.89 Bn |
| CAGR | CAGR of 8.6 % From 2024 to 2031 |
| Base Year | 2023 |
| Forecast Period | 2024-2031 |
| Historical Data | 2020-2022 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Product Type (Prescription Drugs, Orphan, Generics) • By Therapy (Immunosuppressants, Oncology, Sensory Organs, Vaccines, Anticoagulants, Anti-diabetics, Others) • By Distribution Channel (Retail Pharmacies & Drug Stores, Hospital Pharmacies, Online Pharmacies) |
| Regional Analysis/Coverage | North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]). Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East], Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia Rest of Latin America) |
| Company Profiles | Novartis AG, F. Hoffmann-La Roche Ltd, Pfizer, Inc., Johnson & Johnson Services, Inc. Sanofi, AbbVie, Inc., AstraZeneca, Merck & Co., Inc., GlaxoSmithKline pic., CELGENE CORPORATION |
| Key Drivers | • Advances in medical research and technology lead to the discovery of new drug candidates and treatment approaches. • Consumer and Physician Awareness is the driver of the Prescription Drugs Market. |
| Market Restraints | • The pricing of certain prescription drugs, especially for innovative and specialty medications, can be prohibitively high. • The prescription drugs market is being held back by intellectual property challenges. |
Ans. The Compound Annual Growth rate for Prescription Drugs Market over the forecast period is 8.6%.
Ans. USD 1.89 billion is the projected Prescription Drugs market size of the market by 2031.
Ans. Novartis AG and Pfizer, Inc. are the worldwide market leaders.
Ans. North America will have the greatest market share in the Prescription Drugs Market by 2023.
Ans. During the projected period, the other prescription medications category is likely to be the market leader.
Table of Contents
1. Introduction
1.1 Market Definition
1.2 Scope
1.3 Research Assumptions
2. Research Methodology
3. Market Dynamics
3.1 Drivers
3.2 Restraints
3.3 Opportunities
3.4 Challenges
4. Impact Analysis
4.1 Impact of Russia-Ukraine War
4.2 Impact of Ongoing Recession
4.2.1 Introduction
4.2.2 Impact on major economies
4.2.2.1 US
4.2.2.2 Canada
4.2.2.3 Germany
4.2.2.4 France
4.2.2.5 United Kingdom
4.2.2.6 China
4.2.2.7 Japan
4.2.2.8 South Korea
4.2.2.9 Rest of the World
5. Value Chain Analysis
6. Porter’s 5 forces model
7. PEST Analysis
8. Prescription Drugs Market Segmentation, By Product Type
8.1 Prescription Drugs
8.2 Orphan
8.3 Generics
9. Prescription Drugs Market Segmentation, By Therapy
9.1 Immunosuppressants
9.2 Oncology
9.3 Sensory Organs
9.4 Vaccines
9.5 Anticoagulants
9.6 Anti-diabetics
9.7 Others
10. Prescription Drugs Market Segmentation, By Distribution Channel
10.1 Retail Pharmacies & Drug Stores
10.2 Hospital Pharmacies
10.3 Online Pharmacies
11. Regional Analysis
11.1 Introduction
11.2 North America
11.2.1 North America Prescription Drugs Market by Country
11.2.2 North America Prescription Drugs Market by Product Type
11.2.3 North America Prescription Drugs Market by Therapy
11.2.4 North America Prescription Drugs Market by Distribution Channel
11.2.5 USA
11.2.5.1 USA Prescription Drugs Market by Product Type
11.2.5.2 USA Prescription Drugs Market by Therapy
11.2.5.3 USA Prescription Drugs Market by Distribution Channel
11.2.6 Canada
11.2.6.1 Canada Prescription Drugs Market by Product Type
11.2.6.2 Canada Prescription Drugs Market by Therapy
11.2.6.3 Canada Prescription Drugs Market by Distribution Channel
11.2.7 Mexico
11.2.7.1 Mexico Prescription Drugs Market by Product Type
11.2.7.2 Mexico Prescription Drugs Market by Therapy
11.2.7.3 Mexico Prescription Drugs Market by Distribution Channel
11.3 Europe
11.3.1 Eastern Europe
11.3.1.1 Eastern Europe Prescription Drugs Market by Country
11.3.1.2 Eastern Europe Prescription Drugs Market by Product Type
11.3.1.3 Eastern Europe Prescription Drugs Market by Therapy
11.3.1.4 Eastern Europe Prescription Drugs Market by Distribution Channel
11.3.1.5 Poland
11.3.1.5.1 Poland Prescription Drugs Market by Product Type
11.3.1.5.2 Poland Prescription Drugs Market by Therapy
11.3.1.5.3 Poland Prescription Drugs Market by Distribution Channel
11.3.1.6 Romania
11.3.1.6.1 Romania Prescription Drugs Market by Product Type
11.3.1.6.2 Romania Prescription Drugs Market by Therapy
11.3.1.6.4 Romania Prescription Drugs Market by Distribution Channel
11.3.1.7 Turkey
11.3.1.7.1 Turkey Prescription Drugs Market by Product Type
11.3.1.7.2 Turkey Prescription Drugs Market by Therapy
11.3.1.7.3 Turkey Prescription Drugs Market by Distribution Channel
11.3.1.8 Rest of Eastern Europe
11.3.1.8.1 Rest of Eastern Europe Prescription Drugs Market by Product Type
11.3.1.8.2 Rest of Eastern Europe Prescription Drugs Market by Therapy
11.3.1.8.3 Rest of Eastern Europe Prescription Drugs Market by Distribution Channel
11.3.2 Western Europe
11.3.2.1 Western Europe Prescription Drugs Market by Country
11.3.2.2 Western Europe Prescription Drugs Market by Product Type
11.3.2.3 Western Europe Prescription Drugs Market by Therapy
11.3.2.4 Western Europe Prescription Drugs Market by Distribution Channel
11.3.2.5 Germany
11.3.2.5.1 Germany Prescription Drugs Market by Product Type
11.3.2.5.2 Germany Prescription Drugs Market by Therapy
11.3.2.5.3 Germany Prescription Drugs Market by Distribution Channel
11.3.2.6 France
11.3.2.6.1 France Prescription Drugs Market by Product Type
11.3.2.6.2 France Prescription Drugs Market by Therapy
11.3.2.6.3 France Prescription Drugs Market by Distribution Channel
11.3.2.7 UK
11.3.2.7.1 UK Prescription Drugs Market by Product Type
11.3.2.7.2 UK Prescription Drugs Market by Therapy
11.3.2.7.3 UK Prescription Drugs Market by Distribution Channel
11.3.2.8 Italy
11.3.2.8.1 Italy Prescription Drugs Market by Product Type
11.3.2.8.2 Italy Prescription Drugs Market by Therapy
11.3.2.8.3 Italy Prescription Drugs Market by Distribution Channel
11.3.2.9 Spain
11.3.2.9.1 Spain Prescription Drugs Market by Product Type
11.3.2.9.2 Spain Prescription Drugs Market by Therapy
11.3.2.9.3 Spain Prescription Drugs Market by Distribution Channel
11.3.2.10 Netherlands
11.3.2.10.1 Netherlands Prescription Drugs Market by Product Type
11.3.2.10.2 Netherlands Prescription Drugs Market by Therapy
11.3.2.10.3 Netherlands Prescription Drugs Market by Distribution Channel
11.3.2.11 Switzerland
11.3.2.11.1 Switzerland Prescription Drugs Market by Product Type
11.3.2.11.2 Switzerland Prescription Drugs Market by Therapy
11.3.2.11.3 Switzerland Prescription Drugs Market by Distribution Channel
11.3.2.1.12 Austria
11.3.2.12.1 Austria Prescription Drugs Market by Product Type
11.3.2.12.2 Austria Prescription Drugs Market by Therapy
11.3.2.12.3 Austria Prescription Drugs Market by Distribution Channel
11.3.2.13 Rest of Western Europe
11.3.2.13.1 Rest of Western Europe Prescription Drugs Market by Product Type
11.3.2.13.2 Rest of Western Europe Prescription Drugs Market by Therapy
11.3.2.13.3 Rest of Western Europe Prescription Drugs Market by Distribution Channel
11.4 Asia-Pacific
11.4.1 Asia-Pacific Prescription Drugs Market by Country
11.4.2 Asia-Pacific Prescription Drugs Market by Product Type
11.4.3 Asia-Pacific Prescription Drugs Market by Therapy
11.4.4 Asia-Pacific Prescription Drugs Market by Distribution Channel
11.4.5 China
11.4.5.1 China Prescription Drugs Market by Product Type
11.4.5.2 China Prescription Drugs Market by Distribution Channel
11.4.5.3 China Prescription Drugs Market by Therapy
11.4.6 India
11.4.6.1 India Prescription Drugs Market by Product Type
11.4.6.2 India Prescription Drugs Market by Therapy
11.4.6.3 India Prescription Drugs Market by Distribution Channel
11.4.7 japan
11.4.7.1 Japan Prescription Drugs Market by Product Type
11.4.7.2 Japan Prescription Drugs Market by Therapy
11.4.7.3 Japan Prescription Drugs Market by Distribution Channel
11.4.8 South Korea
11.4.8.1 South Korea Prescription Drugs Market by Product Type
11.4.8.2 South Korea Prescription Drugs Market by Therapy
11.4.8.3 South Korea Prescription Drugs Market by Distribution Channel
11.4.9 Vietnam
11.4.9.1 Vietnam Prescription Drugs Market by Product Type
11.4.9.2 Vietnam Prescription Drugs Market by Therapy
11.4.9.3 Vietnam Prescription Drugs Market by Distribution Channel
11.4.10 Singapore
11.4.10.1 Singapore Prescription Drugs Market by Product Type
11.4.10.2 Singapore Prescription Drugs Market by Therapy
11.4.10.3 Singapore Prescription Drugs Market by Distribution Channel
11.4.11 Australia
11.4.11.1 Australia Prescription Drugs Market by Product Type
11.4.11.2 Australia Prescription Drugs Market by Therapy
11.4.11.3 Australia Prescription Drugs Market by Distribution Channel
11.4.12 Rest of Asia-Pacific
11.4.12.1 Rest of Asia-Pacific Prescription Drugs Market by Product Type
11.4.12.2 Rest of Asia-Pacific Prescription Drugs Market by Therapy
11.4.12.3 Rest of Asia-Pacific Prescription Drugs Market by Distribution Channel
11.5 Middle East & Africa
11.5.1 Middle East
11.5.1.1 Middle East Prescription Drugs Market by Country
11.5.1.2 Middle East Prescription Drugs Market by Product Type
11.5.1.3 Middle East Prescription Drugs Market by Therapy
11.5.1.4 Middle East Prescription Drugs Market by Distribution Channel
11.5.1.5 UAE
11.5.1.5.1 UAE Prescription Drugs Market by Product Type
11.5.1.5.2 UAE Prescription Drugs Market by Therapy
11.5.1.5.3 UAE Prescription Drugs Market by Distribution Channel
11.5.1.6 Egypt
11.5.1.6.1 Egypt Prescription Drugs Market by Product Type
11.5.1.6.2 Egypt Prescription Drugs Market by Therapy
11.5.1.6.3 Egypt Prescription Drugs Market by Distribution Channel
11.5.1.7 Saudi Arabia
11.5.1.7.1 Saudi Arabia Prescription Drugs Market by Product Type
11.5.1.7.2 Saudi Arabia Prescription Drugs Market by Therapy
11.5.1.7.3 Saudi Arabia Prescription Drugs Market by Distribution Channel
11.5.1.8 Qatar
11.5.1.8.1 Qatar Prescription Drugs Market by Product Type
11.5.1.8.2 Qatar Prescription Drugs Market by Therapy
11.5.1.8.3 Qatar Prescription Drugs Market by Distribution Channel
11.5.1.9 Rest of Middle East
11.5.1.9.1 Rest of Middle East Prescription Drugs Market by Product Type
11.5.1.9.2 Rest of Middle East Prescription Drugs Market by Therapy
11.5.1.9.3 Rest of Middle East Prescription Drugs Market by Distribution Channel
11.5.2 Africa
11.5.2.1 Africa Prescription Drugs Market by Country
11.5.2.2 Africa Prescription Drugs Market by Product Type
11.5.2.3 Africa Prescription Drugs Market by Therapy
11.5.2.4 Africa Prescription Drugs Market by Distribution Channel
11.5.2.5 Nigeria
11.5.2.5.1 Nigeria Prescription Drugs Market by Product Type
11.5.2.5.2 Nigeria Prescription Drugs Market by Therapy
11.5.2.5.3 Nigeria Prescription Drugs Market by Distribution Channel
11.5.2.6 South Africa
11.5.2.6.1 South Africa Prescription Drugs Market by Product Type
11.5.2.6.2 South Africa Prescription Drugs Market by Therapy
11.5.2.6.3 South Africa Prescription Drugs Market by Distribution Channel
11.5.2.7 Rest of Africa
11.5.2.7.1 Rest of Africa Prescription Drugs Market by Product Type
11.5.2.7.2 Rest of Africa Prescription Drugs Market by Therapy
11.5.2.7.3 Rest of Africa Prescription Drugs Market by Distribution Channel
11.6 Latin America
11.6.1 Latin America Prescription Drugs Market by Country
11.6.2 Latin America Prescription Drugs Market by Product Type
11.6.3 Latin America Prescription Drugs Market by Therapy
11.6.4 Latin America Prescription Drugs Market by Distribution Channel
11.6.5 Brazil
11.6.5.1 Brazil America Prescription Drugs Market by Product Type
11.6.5.2 Brazil America Prescription Drugs Market by Therapy
11.6.5.3 Brazil America Prescription Drugs Market by Distribution Channel
11.6.6 Argentina
11.6.6.1 Argentina America Prescription Drugs Market by Product Type
11.6.6.2 Argentina America Prescription Drugs Market by Therapy
11.6.6.3 Argentina America Prescription Drugs Market by Distribution Channel
11.6.7 Colombia
11.6.7.1 Colombia America Prescription Drugs Market by Product Type
11.6.7.2 Colombia America Prescription Drugs Market by Therapy
11.6.7.3 Colombia America Prescription Drugs Market by Distribution Channel
11.6.8 Rest of Latin America
11.6.8.1 Rest of Latin America Prescription Drugs Market by Product Type
11.6.8.2 Rest of Latin America Prescription Drugs Market by Therapy
11.6.8.3 Rest of Latin America Prescription Drugs Market by Distribution Channel
12 Company profile
12.1 Novartis AG
12.1.1 Company Overview
12.1.2 Financials
12.1.3 Product/Services Offered
12.1.4 SWOT Analysis
12.1.5 The SNS View
12.2 F. Hoffmann-La Roche Ltd
12.2.1 Company Overview
12.2.2 Financials
12.2.3 Product/Services Offered
12.2.4 SWOT Analysis
12.2.5 The SNS View
12.3 Pfizer, Inc
12.3.1 Company Overview
12.3.2 Financials
12.3.3 Product/Services Offered
12.3.4 SWOT Analysis
12.3.5 The SNS View
12.4 Johnson & Johnson Services, Inc
12.4.1 Company Overview
12.4.2 Financials
12.4.3 Product/Services Offered
12.4.4 SWOT Analysis
12.4.5 The SNS View
12.5 Sanofi
12.5.1 Company Overview
12.5.2 Financials
12.5.3 Product/Services Offered
12.5.4 SWOT Analysis
12.5.5 The SNS View
12.6 AbbVie, Inc.
12.6.1 Company Overview
12.6.2 Financials
12.6.3 Product/Services Offered
12.6.4 SWOT Analysis
12.6.5 The SNS View
12.7 AstraZeneca
12.7.1 Company Overview
12.7.2 Financials
12.7.3 Product/Services Offered
12.7.4 SWOT Analysis
12.7.5 The SNS View
12.8 Merck & Co., Inc.
12.8.1 Company Overview
12.8.2 Financials
12.8.3 Product/Services Offered
12.8.4 SWOT Analysis
12.8.5 The SNS View
12.9 GlaxoSmithKline pic.
12.9.1 Company Overview
12.9.2 Financials
12.9.3 Product/Services Offered
12.9.4 SWOT Analysis
12.9.5 The SNS View
12.10 CELGENE CORPORATION
12.10.1 Company Overview
12.10.2 Financials
12.10.3 Product/Services Offered
12.10.4 SWOT Analysis
12.10.5 The SNS View
13. Competitive Landscape
13.1 Competitive Benchmarking
13.2 Market Share Analysis
13.3 Recent Developments
13.3.1 Industry News
13.3.2 Company News
13.3.3 Mergers & Acquisitions
14. Use Case and Best Practices
15. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
Hearing Aids Market size was valued at USD 10.88 Billion in 2023 and is expected to reach USD 20.87 Billion By 2031 and grow at a CAGR of 8.5% over the forecast period of 2024-2031.
The Dental X-Ray Market Size was valued at USD 2.9 billion in 2022, and is expected to reach USD 5.48 billion by 2030 and grow at a CAGR of 8.3% over the forecast period 2023-2030.
The Virtual Clinical Trials Market Size was valued at USD 7.91 billion in 2022, and is expected to reach USD 12.14 billion by 2030 and grow at a CAGR of 5.5% over the forecast period 2023-2030.
The Urinary Drainage Bags Market size was valued at USD 2.71 billion in 2023 and it is expected to be worth around USD 3.75 billion by 2031 growing at a remarkable GAGR of 4.86% over the forecast period 2024-2031.
The Healthcare Workforce Management Systems Market Size was valued at USD 1.77 billion in 2022, and is expected to reach USD 4.79 billion by 2030, and grow at a CAGR of 13.2% over the forecast period 2023-2030.
The Over-The-Counter Drugs Market size was valued at USD 175.6 billion in 2023 and is expected to reach at USD 275.7 billion by 2031, and grow at a CAGR of 5.80% over the forecast period of 2024-2031.
Hi! Click one of our member below to chat on Phone
© 2024 All Rights Reserved by SNS Insider Pvt Ltd
